Kate Rochlin

Chief Operating Officer at IN8bio

Advisor

Kate has served as IN8bio’s Chief Operating Officer since 2021 and previously as their VP, Operations and Innovation. She has 18+ years of expertise in strategic company development & operations, IP, CMC, and clinical manufacturing of advanced therapies. She was previously the Chief Business Officer at Curadigm, a Cambridge-based spin-out of Nanobiotix focused on RNA therapeutic bioavailability. Prior, Dr. Rochlin co-founded and served as CSO at Immunovent in New York City. Dr. Rochlin earned a Ph.D. in Molecular Biology and Genetics from Weill Cornell Medical College, researched at Sloan Kettering Institute, and a BA from the University of Pennsylvania.